Royalty Pharma (RPRX) Q1 FY25 earnings call

Royalty Pharma delivered a strong Q1 FY25, driven by robust portfolio performance and strategic capital allocation. The company raised its full-year guidance for portfolio receipts, reflecting underlying strength and a favorable FX tailwind. Management actively returned capital to shareholders through significant share repurchases while continuing to invest in attractive royalty assets and advancing its pipeline.